A dopamine reuptake inhibitor (DRI) is a class of drug which acts as a reuptake inhibitor of the monoamine neurotransmitter dopamine by blocking the action of the dopamine transporter (DAT, aka SLC6A3) (Tatsumi et al. 1997, Richelson 2001). The result is increased extracellular concentrations of dopamine and an increase in dopaminergic neurotransmission. DRIs are used in the treatment of attention-deficit hyperactivity disorder (ADHD) and narcolepsy for their psychostimulant effects (eg. bupropion, dexamfetamine, dexmethylphenidate and methyphenidate), and in the treatment of obesity and binge eating disorder for their appetite suppressant effects (eg. mazindol). Trimipramine has antihistamine, antiserotonergic, antiadrenergic, antidopaminergic, and anticholinergic activities but is primarily used to treat depression, anxiety and insomnia (Pecknold & Luthe 1989).